CK Life Sciences International

What CK Life Sciences International does

CK Life Sciences Int'l., (Holdings) Inc. is a Hong Kong-listed diversified life sciences holding company (founded 2002, member of the CK Hutchison Group) operating across three core segments: agriculture-related businesses, nutraceuticals, and pharmaceuticals & diagnostics R&D. Its agriculture-related operations include Belvino Investments Trust (vineyards of approximately 3,000 hectares across Australia and New Zealand, leased to major wine companies), Australian Agribusiness (Accensi for plant protection manufacturing and Amgrow for distribution across professional turf, pest management, home garden, and specialty agriculture), and Cheetham Salt Group (the largest salt producer in Australia, New Zealand, and Indonesia, with ~900,000 tonnes crude salt capacity per annum). The nutraceutical segment comprises Santé Naturelle A.G. (Adrien Gagnon brand, 140+ natural health products in Canada), Vitaquest (US contract manufacturing, 4,000+ custom formulas for 500+ brands in 40 countries), and Lipa Pharmaceuticals (Australia's largest contract manufacturer of complementary healthcare medicines).

The pharmaceutical and diagnostics R&D segment is built around three proprietary platforms: seviprotimut-L, a polyvalent melanoma cancer vaccine with FDA Fast Track designation and Special Protocol Assessment agreement for Phase III in Stage IIB/IIC adjuvant melanoma (developed by Polynoma LLC in San Diego); Halneuron®, a non-opioid, non-addictive tetrodotoxin-based analgesic blocking Nav1.7 sodium channels, currently in Phase IIB for chemotherapy-induced neuropathic pain (development now housed in NASDAQ-listed Dogwood Therapeutics, formed via the October 2024 merger of WEX Pharmaceuticals and Virios Therapeutics); and OncoSweep™, a liquid biopsy diagnostic platform for early cancer detection via tumor-associated biomarkers, with a 2024 exclusive worldwide license with City of Hope for pancreatic cancer microRNA biomarkers (via Pharus, Inc.). In March 2026, the company established Sequencio Therapeutics Company Limited to advance therapeutic cancer vaccine development, and pursues an AI-empowered cancer vaccine R&D collaboration with XtalPi Inc. leveraging AI algorithms for neoantigen peptide vaccine design.

The company monetizes through diversified revenue streams: long-term vineyard leases, agrichemical contract manufacturing and distribution, salt and refined salt product sales, nutraceutical B2B contract manufacturing and B2C retail distribution, and pre-commercial pharmaceutical R&D with no current licensing revenue. Customer base spans enterprise tenants (wine companies, agrichemical firms), B2B brand clients (500+ nutraceutical brands), and consumer health segments across North America, Australia/NZ, Asia, the Middle East, and Africa. The company is controlled by CK Hutchison Holdings Limited, with Mr. Li Tzar Kuoi, Victor as Chairman and a 2024-promoted Deputy Chairman and CEO. A CEO resignation was announced in May 2026, indicating near-term leadership transition.

Name

CK Life Sciences International

Legal name

CK Life Sciences Int'l., (Holdings) Inc.

Website

https://ck-lifesciences.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

CK Life Sciences is a Hong Kong-listed diversified life sciences holding company (member of CK Hutchison Group) operating agriculture-related businesses (vineyards, plant protection, salt), nutraceutical contract manufacturing and brands, and pharmaceuticals & diagnostics R&D focused on cancer vaccines, non-opioid pain therapeutics, and liquid biopsy diagnostics.

Ownership category

akta.pro rank

Product category

Diversified Life Sciences and Healthcare

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ)

akta.pro secondary industries

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Therapeutic cancer vaccines
• Nutraceutical contract manufacturing
• Agricultural bioscience products
• Salt production refining
• Liquid biopsy diagnostics

Headquarters

HQ city

Tai Po

HQ country

Hong Kong SAR China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Agriculture-related Business: Revenue from vineyard operations (long-term leases to wine companies), Australian agribusiness (manufacturing and distribution of plant protection, nutrition, and pest management products through Accensi and Amgrow), and salt production (Cheetham Salt Group - largest producer in Australia, New Zealand, and Indonesia). Includes manufacturing services to domestic and multinational agrichemical companies.
2. Nutraceutical Business: Revenue from health product manufacturing and sales through subsidiaries: Santé Naturelle A.G. (natural health products in Canada, 140+ products), Vitaquest (contract development and manufacturing in US, 4000+ custom formulas for 500+ brands), and Lipa Pharmaceuticals (contract manufacturing of complementary healthcare medicines in Australia). Products sold under brands like Adrien Gagnon across retail channels.
3. Pharmaceuticals & Diagnostics R&D: Revenue stream from pharmaceutical development through subsidiaries: Polynoma (therapeutic cancer vaccines including seviprotimut-L in Phase III), Dogwood Therapeutics (Halneuron® pain management in Phase IIB), and strategic investment in Pharus (liquid biopsy diagnostics). Currently in R&D stage with pipeline candidates in clinical and discovery stages.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

CK Life Sciences is a diversified life sciences company that operates three core business areas: (1) agriculture-related businesses including vineyard leasing, plant protection products manufacturing and distribution, and salt production in Australasia; (2) nutraceutical businesses comprising natural health products under brands like Adrien Gagnon and contract manufacturing of vitamins and supplements; and (3) pharmaceuticals and diagnostics R&D focused on therapeutic cancer vaccines (seviprotimut-L), non-opioid pain management (Halneuron), and liquid biopsy cancer diagnostics (OncoSweep). The company's operating businesses generate cash flow to sustain its healthcare R&D pipeline.

Product overview

CK Life Sciences International is a diversified life sciences company with a portfolio of businesses spanning three core areas: (1) Agriculture-related businesses including vineyard operations (Belvino Investments Trust), Australian Agribusiness (Accensi and Amgrow), and Cheetham Salt Group; (2) Nutraceutical businesses including Santé Naturelle A.G., Vitaquest, and Lipa Pharmaceuticals; and (3) Pharmaceuticals & Diagnostics R&D focused on therapeutic cancer vaccines (Seviprotimut-L), pain management (Halneuron®), cancer diagnostics (OncoSweep™), and AI-empowered cancer vaccine development in partnership with XtalPi. The company operates as a multi-business holding company with subsidiaries across Australia, North America, and Asia, all supporting its R&D sustainability mission.

Differentiator

Problem solved

Functional benefit

Brands

• Seviprotimut-L: Proprietary polyvalent melanoma cancer vaccine developed by Polynoma LLC for adjuvant treatment of Stage IIB or IIC melanoma
• Halneuron
• OncoSweep
• ADRIEN GAGNON
• Polynoma
• Sequencio Therapeutics

Quantifiable outcome

• Global melanoma market exceeds US$1 billion with approximately 350,000 cases and nearly 60,000 deaths annually worldwide
• +2 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Dogwood TherapeuticscoreStrategic or Co-development Partner · 1 October 2024Dogwood Therapeutics (NASDAQ: DWTX) was formed after merger between CK Life Sciences' subsidiary WEX Pharmaceuticals and Virios Therapeutics in October 2024. WEX Pharmaceuticals developed Halneuron® (tetrodotoxin-based non-opioid analgesic). Development continues for Phase IIB clinical trial of Halneuron® for chemotherapy-induced neuropathic pain.
• City of HopecoreTechnology or Integration · 1 January 2024Worldwide exclusive license agreement signed by Pharus (CK Life Sciences' strategic investment) with City of Hope, a major U.S. cancer center, for proprietary microRNA biomarkers relevant to the early detection of pancreatic cancer. Part of liquid biopsy diagnostic development program.
• XtalPi Inc.coreStrategic or Co-development PartnerStrategic R&D collaboration with XtalPi Inc., a Shenzhen-headquartered technology company specializing in drug discovery powered by AI and automation. Collaboration aims to develop an advanced cancer vaccine R&D platform to enhance discovery and development of new cancer vaccines using AI algorithms to design potential mutated neoantigen peptide cancer vaccines.
• Polynoma LLCcoreStrategic or Co-development PartnerOncology-focused subsidiary of CK Life Sciences based in San Diego, developing seviprotimut-L, a proprietary polyvalent melanoma cancer vaccine. Received FDA Fast Track designation and Special Protocol Assessment agreement for pivotal Phase III clinical study. Results from earlier trials showed encouraging recurrence-free survival data.

Scale indicators8 records

Recent moves7 records

Expansion highlights10 records

Regional players

• GrainCorp Limited: Australian-listed agribusiness focused on grain handling, storage, processing, and marketing across eastern Australia. Comparable as a regional agribusiness peer operating in Australian agricultural value chains with exposure to commodity and seasonal cycles.
• Incitec Pivot Limited: Australian-listed fertilizer, chemicals, and explosives manufacturer serving agriculture, mining, and infrastructure customers in Australia and globally. Comparable as a regional agribusiness and specialty chemicals manufacturer with overlapping end markets in Australian agriculture.
• Ridley Corporation Limited: Australian-listed animal nutrition and agriservices company producing stockfeed and supplements for the Australasian rural sector. Comparable as a regional agribusiness peer with similar exposure to Australian agricultural markets and supply chains.

Broad incumbents

• Sino Biopharmaceutical Limited: Major HK-listed Chinese pharmaceutical conglomerate with a diversified drug portfolio across oncology, hepatology, respiratory, and cardiovascular therapeutic areas. Comparable as a Hong Kong-listed diversified life sciences company with both commercial pharmaceutical operations and R&D investment.
• Nufarm Limited: Australian-listed crop protection and seed company with global manufacturing and distribution across crop chemicals, seeds, and agritech. Comparable for CK Life Sciences' Accensi and Amgrow agricultural chemicals manufacturing and distribution operations serving the Australian and New Zealand markets.
• Blackmores Limited: Leading Australasian natural health and nutraceutical company with a portfolio of vitamins, minerals, herbal supplements, and self-care products. Comparable as a major player in the Australasian consumer health/nutraceutical market where CK Life Sciences operates through Santé Naturelle A.G. and Lipa Pharmaceuticals.
• CSL Limited: Australia's largest biotechnology company and global leader in plasma-derived therapies and vaccines with operations across North America, Europe, and Asia-Pacific. Comparable as a major Australian-headquartered life sciences company with global scale and significant R&D investment.

Emerging players

• Botanix Pharmaceuticals Limited: Australian-listed clinical-stage dermatology and cannabinoid biotechnology company developing novel therapeutic platforms. Comparable as an emerging Australian-listed life sciences company pursuing clinical development with novel mechanisms of action.

Direct peers

• HUTCHMED (China) Limited: Sister company under CK Hutchison Holdings, listed on HKEX, NASDAQ, and LSE; an oncology and immunology-focused biopharma developing late-stage therapeutics including surufatinib and savolitinib. Most directly comparable as a CK Group life sciences innovator with clinical-stage drug development.
• Compass Minerals International: NYSE-listed global salt and specialty plant-nutrition producer operating salt mines and production facilities in North America and the UK. Comparable as a direct peer to CK Life Sciences' Cheetham Salt Group for industrial and food-grade salt production with similar commodity-cycle dynamics and scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CK Life Sciences International